Protocol Ledger

NCT05718375 · Phase II · COMPLETED

Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Interventional Phase II clinical trial protocol NCT05718375 sponsored by Curacle Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-14 Enrollment: 240 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05718375
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05718375
Protocol FieldVerified Registry Value
NCT IdentifierNCT05718375
Consolidated Lead SponsorCuracle Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment240 participants (ACTUAL)
Registered Start Date2023-02-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05718375
Hospital Research SiteLocationSite Profile
Pusan National University HospitalBusan, South KoreaOpen Hospital Dossier ->
Keimyung University, Dongsan hospitalDaegu, South KoreaOpen Hospital Dossier ->
Kyungpook National University Chilgok HospitalDaegu, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI